DRMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Dermata Therapeutics Inc (DRMA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits a bearish technical trend, poor financial performance, and lacks positive catalysts or institutional support. Additionally, no significant trading signals or news events suggest an immediate opportunity.
The stock shows a bearish trend with MACD below 0 and negatively expanding, RSI at 25.834 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 1.377 and S2 at 1.009.
No positive catalysts identified. No recent news or significant insider/hedge fund activity.
also closed with a -1.54% change, indicating a negative sentiment.
In Q3 2025, the company reported zero revenue growth (0% YoY), a net income drop of -46.68% YoY to -$1,691,989, and a drastic EPS decline of -91.92% YoY to -1.65. Gross margin remains at 0%.
No analyst ratings or price target changes available.
